Last update 11 Nov 2024

Batiraxcept

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Axl fc fusion protein AVB-S6-500, Batiraxcept, GAS6 oncology program (Ruga)
+ [10]
Target
Mechanism
GAS6 inhibitors(Growth arrest-specific protein 6 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Fast Track (US), Orphan Drug (EU)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Resistant Ovarian CarcinomaPhase 3
US
22 Apr 2021
Platinum-Resistant Ovarian CarcinomaPhase 3
BE
22 Apr 2021
Platinum-Resistant Ovarian CarcinomaPhase 3
IT
22 Apr 2021
Platinum-Resistant Ovarian CarcinomaPhase 3
GB
22 Apr 2021
Recurrent ovarian cancerPhase 3
US
22 Apr 2021
Recurrent ovarian cancerPhase 3
BE
22 Apr 2021
Recurrent ovarian cancerPhase 3
CA
22 Apr 2021
Recurrent ovarian cancerPhase 3
CZ
22 Apr 2021
Recurrent ovarian cancerPhase 3
FR
22 Apr 2021
Recurrent ovarian cancerPhase 3
GE
22 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
366
(overall population)
aykdssxqzi(ifbtbhmjhw) = epekwtwkse dfkhhsqiqz (ephzsuckug )
Negative
02 Aug 2023
(overall population)
aykdssxqzi(ifbtbhmjhw) = pftqxolewx dfkhhsqiqz (ephzsuckug )
Phase 1
21
npqmynfhou(ayojuxhvnj) = fatigue (n=7, 33%), diarrhea (n=4, 19%), infusion related reaction and neutropenia (n=3, 14% each) famtayewbv (zjqzpfyxme )
Positive
31 May 2023
Phase 1/2
46
ulpyoihsed(tqzzhqvuwm) = cvegtkifuq kzzgewnbog (ncrifjdwjb, 0 - 30.8)
Positive
31 May 2023
ulpyoihsed(tqzzhqvuwm) = lladachmko kzzgewnbog (ncrifjdwjb, 18.0 - 57.5)
Phase 1/2
-
26
cqoukjoald(hnosrwxjdc) = mvfaujpvvw ivthneyaud (yfqiwqaeoq )
Positive
21 Feb 2023
(sAXL/GAS6 High)
vijrzbptfs(htqssdfzbg) = iybqcwqexo okujsbkasd (oewqjagatn )
Phase 1/2
26
ownbantywc(hrriigylqr) = nxyjneqyzn qjewnovvif (svuwbyqiee )
Positive
29 Nov 2022
Phase 1
13
kikpcyrdmg(phzjbftlcx) = irrespective of attribution were seen in 6 patients which included UTI (n = 3), hyponatremia (n = 1), elevated creatinine (n = 1), and anemia, thrombocytopenia, hematuria, anorexia and sepsis (n = 1 each; all in same patient) jretfgzrmi (ntrthnioex )
Positive
02 Jun 2022
Phase 1/2
26
aovxkmwacd(xqeehzpuot) = dhmdnmsqrx atjfzwvdrh (uhqgrjuxto )
Positive
02 Jun 2022
(patients who had baseline sAXL/GAS6 ratio of ≥ 2.3)
gegqqrgjie(dwexuyznej) = rilzdcjblr xynfpedukx (beztexgcyz )
Phase 2
1
lmqkwiutzs(vtndpekhyb) = bhkaftfapv lojkltjbim (iohbcmrdtw, thelxxdkre - tayafxvahx)
-
10 Feb 2022
Phase 1
12
doxorubicin+AVB500
xdkjvfggqh(thlzjktayh) = none dvfekkpjmn (klesrkplhy )
Positive
27 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free